drugset
drugset / Trial / NCT02436993

Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab

NCT02436993 ↗

Phase 2 Active not recruiting 120 enrolled University of California, Irvine
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this phase II is to study the efficacy and toxicity of carboplatin and paclitaxel with pertuzumab and trastuzumab in HER2 positive and carboplatin and paclitaxel with bevacizumab in HER2 negative in the neoadjuvant setting for the treatment of breast cancer.

Timeline

Start
2015-04
Primary completion
2023-11
Completion
2036-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody 10 mg/kg Intravenous
Subject Carboplatin Small molecule 2 unknown Intravenous
Subject Paclitaxel Small molecule 80 mg/m2 Intravenous
Subject Pertuzumab Monoclonal antibody 420 mg Intravenous
Subject Trastuzumab Monoclonal antibody 2 mg/kg Intravenous

Indications

breast carcinoma